Boehringer Ingelheim announces FDA approval of Twynsta

Boehringer Ingelheim has announced the Food and Drug Administration’s (FDA) approval of its blood pressure reduction treatment Twynsta (telmisartan plus amlodipine).

The drug is a single pill combination therapy that delivers powerful blood pressure reductions of up to 40/29 mmHg, as well as a 24-hour response rate of 98 per cent maximum.

Twynsta has also been shown to achieve superior BP reductions compared to amlodipine 10 mg doses alone.

It is indicated for use in hypertensive patients at risk of cardiovascular events.

Corporate vice-president of medical affairs at the firm Professor Klaus Dugi stated: “With its excellent safety profile and demonstrated efficacy, Twynsta will help physicians and patients to overcome common barriers to effective blood pressure control, such as treatment adherence.”

Last week, the European commission approved Boehringer Ingelheim’s once-daily prolonged-release tablet therapy Mirapexin/Sifrol (pramipexole).